DAMGO
| DAMGO | |
|---|---|
| |
| IUPAC name | (2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl) propanoyl]amino]propanoyl]amino]acetyl]-methylamino]- N-(2-hydroxyethyl)-3-phenylpropanamide |
| Other names | Ala2-MePhe4-Gly5-Enkephalin, DAGO, DAMGE |
| Identifiers | |
| CAS number | |
| PubChem | |
| SMILES | CC(C(=O)NCC(=O)N(C)C(CC1=CC=CC=C1)C (=O)NCCO)NC(=O)C(CC2=CC=C(C=C2)O)N |
| Properties | |
| Molecular formula | C26H35N5O6 |
| Molar mass | 513.59 g mol-1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) is a synthetic opioid peptide with high μ-opioid receptor specificity. It was synthesized as a biologically stable analog of δ-opioid receptor-preferring endogenous opioids, leu- and met-enkephalin.[1]
Its structure is H-Tyr-D-Ala-Gly-N-MePhe-Gly-OH.
References
- ↑ Handa BK, Land AC, Lord JA, Morgan BA, Rance MJ, Smith CF. "Analogues of β-LPH61–64 possessing selective agonist activity at μ-opiate receptors." European Journal of Pharmacology. 1981 Apr 9;70(4):531-40. PMID 6263640. doi:10.1016/0014-2999(81)90364-2
Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added
Pictures
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
